Cardioprotective effects of anisodamine against myocardial ischemia/reperfusion injury through the inhibition of oxidative stress, inflammation and apoptosis

BAO-JU YAO1*, XIAO-QING HE2*, YU-HUI LIN2 and WEN-JUN DAI2

1Department of Cardiology, The First People's Hospital of Huainan, Huainan, Anhui 232007; 2Department of Cardiology, The Third Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong 510150, P.R. China

Received November 26, 2016; Accepted July 12, 2017

Abstract. The aim of the present study was to investigate the cardioprotective effects of anisodamine against myocardial ischemia/reperfusion (I/R) injury and the molecular mechanisms involved. The present results demonstrated that anisodamine attenuated myocardial infarct sizes, decreased the levels of creatine kinase and lactate dehydrogenase, whereas it increased the left ventricular (LV) systolic pressure, the LV end-diastolic pressure, and the LV pressure maximum rising and falling rates in a myocardial I/R rat model. In addition, anisodamine was revealed to suppress oxidative stress, inflammatory factor production and myocardial cell apoptosis, as demonstrated by the downregulation of caspase-3 and apoptosis regulator BAX protein expression. The production of reactive oxygen species was decreased and the protein expression of inducible nitric oxide synthase (iNOS) was downregulated, whereas the expression of endothelial NOS was enhanced. In addition, the activity of nicotinamide-adenine dinucleotide phosphate oxidase (Nox) was suppressed and the expression of Nox4 was downregulated in rats with myocardial I/R injury. In conclusion, the results of the present study suggested that anisodamine exerted a cardioprotective effect against myocardial I/R injury in rats, through the inhibition of oxidative stress, the suppression of inflammatory processes and the inhibition of myocardial cell apoptosis.

Introduction

As a result of current lifestyle and dietary habits, the morbidity of atherosclerotic coronary heart disease (CHD) is constantly increasing, placing CHD among the most serious threats to human health worldwide (1). In 2008, in the Global Health Statistical Report of the World Health Organization (WHO), cardiovascular and cerebrovascular diseases were reported to be the second leading cause of human mortality, following malignant tumors (2). In May 2014, the WHO updated the evaluation report regarding global health, indicating that ischemic heart disease, apoplexy, chronic obstructive pulmonary disease and lower respiratory infection are the four major causes of human mortality (3). Globally, ~7 million people succumb to ischemic heart disease and ~50% of patients succumb to myocardial ischemia/reperfusion (I/R) injury. The morbidity of myocardial I/R injury increases every year, thus posing a serious threat to global health and making myocardial infarction one of the most important public health concerns currently (4).

Apoptosis is a type of programmed cell death; it is a highly-regulated process involving specific mechanisms, that is activated in mammalian cells under certain conditions. During apoptosis, endogenous DNA-degrading enzymes are activated resulting in cell death (5). Somatic cell death is a result of necrosis or apoptosis (6); these two types of cell death differ in their functions, molecular mechanisms and biochemistry.

Under ischemic conditions, the enzymatic activity of myocardial cells is severely compromised; as a result, during reperfusion, the restoration of oxygen supply further damages myocardial cells (7). During reperfusion, the generation of reactive oxygen species (ROS) is enhanced (7). ROS can destroy the structure of cell membranes through lipid peroxidation (8), thus causing an increase in membrane permeability, resulting in cellular edema. The structure of the mitochondrial membrane is also compromised, thus damaging mitochondrial function and impairing energy production, further aggravating cellular injury. ROS can oxidize proteins and impair their functions (9). When membrane protein functions are impaired, the ion exchange processes are inhibited; this is one of the primary causes of intracellular Ca2+ overload. ROS promote the chemotaxis of white blood cells; they also activate various enzymes and promote the release of prostaglandins and leukotrienes, thus further aggravating tissue damage (9). In addition, ROS can destroy nucleic acids and chromosomes; the
resulting DNA damage also activates the pathways leading to cell apoptosis or necrosis, thus further promoting myocardial I/R injury (10).

Inflammatory processes are among the most important mechanisms implicated in the pathophysiology of myocardial I/R injury. During inflammatory reactions, the infiltration of polymorphonuclear neutrophils (PMNs) is critical (11). In I/R injury, microvascular endothelial cells and the blood vessel endothelium are damaged, attracting the adhesion of PMNs in the endothelial tissue (12). The inflammatory reaction is initiated by PMNs attachment to the blood vessel endothelium (12). This results in the increased generation of oxygen free radicals and the activation of various proteases, thus altering vascular permeability (13,14). Once activated, PMNs change shape, making it difficult to penetrate through the tissues; thus, they are concentrated in the blood vessel endothelium, resulting in tissue damage and endothelial dysfunction (12,13). Activated PMBs also secrete proinflammatory cytokines, including interleukin (IL)-1, IL-6 and tumor necrosis factor (TNF)-α. Cytokines further activate the inflammatory response through nuclear factor-κB signaling, potentiating the release of inflammatory mediators, thus forming a vicious cycle, and promoting the development and progression of I/R injury (12).

Anisodamine is a cholinergic and α1 adrenergic receptor antagonist, which has been used in China for the treatment of coronary heart disease, for the prevention and treatment of angina, pulmonary hypertension and chronic heart failure, in combination with cardiac glycosides or diuretic agents (15,16). The present study aimed to investigate the putative cardioprotective effects of anisodamine against myocardial I/R injury, and to explore the underlying molecular mechanisms, using an in vivo rat model of I/R injury.

Materials and methods

Animal experiments and ethical approval. Adult male Sprague-Dawley rats (n=24; weight, 220-250 g; 8-10 weeks) were provided by the Experimental Animal Center of the Third Affiliated Hospital of Guangzhou Medical University (Guangzhou, China). All experimental protocols used in the present study were approved by Committee on Animal Research and Ethics of Guangzhou Medical University (Guangzhou, China). The rats were maintained in a temperature-controlled facility, at 22±2°C, with a relative humidity of 55±10%, under a 12-h light/dark cycle, and food and water ad libitum.

Myocardial I/R. All rats were randomly distributed into three groups (8 rats/group): Control group (sham-operated group); MI/R group (myocardial ischemia/reperfusion injury group); and ANI group (anisodamine treatment group). Rats were anesthetized with sodium pentobarbital (30 mg/kg, intraperitoneally), and the following surgical procedure was performed: The trachea was cannulated with a PE-90 catheter and rats were ventilated with O2 and CO2, maintaining a tidal volume of 0.8-1.2 ml. Following a left thoracotomy, the left anterior descending was exposed and occluded by ligation with a 5-0 silk suture. Myocardial ischemia was maintained for 1 h. After that, the ligation was removed, and rats were reperfused for 2 h and treated with anisodamine. In control group, rat was anesthetized with sodium pentobarbital (30 mg/kg, intraperitoneally) and the surgical procedure was performed without ligation. In anisodamine treatment group, the rats were gavaged with 25 mg/kg of anisodamine (Shanghai Xinyijinzhu Pharmaceutical Co., Ltd., Shanghai, China) for 7 days. In sham group, rat was only anesthetized with sodium pentobarbital (30 mg/kg, intraperitoneally).

**Myocardial infarct size.** Hearts were harvested following treatment with anisodamine for 7 days and washed 3 times with normal saline. Heart tissue was fixed with 5% parafomaldehyde for 24 h and sliced into 1-mm transverse sections and stained with 1% 2,3,5-triphenyltetrazolium chloride at room temperature for 1 h. Subsequently, infarct sizes were observed using inverted microscope (Leica Microsystems GmbH, Wetzlar, Germany) and analyzed using ImageJ software version 1.43 (National Institutes of Health, Bethesda, MD, USA). Necrotic area was the white area and area at risk was determined as white area/total area x100%.

Assessment of cardiac function. Following anesthesia, the rats were secured in a supine position, an indwelling arterial needle was inserted into the right carotid artery, and the BL-420 Biological data acquisition and analysis system (Chengdu Thaimeng Software Co., Ltd., Chengdu, China) was used to measure the left ventricular (LV) systolic pressure (LVP) and the LV end-diastolic pressure (LVEDP). The LV pressure maximum rising and falling rates (+dp/dtmax, -dp/dtmax) were analyzed using Isoheart Software, version 1.5 (Hugo Sachs Electronic, March-Hugstetten, Germany).

**ELISA assays.** The levels of creatine kinase (CK), lactate dehydrogenase (LDH), proinflammatory factors and oxidative stress markers, as well as the activity of caspase-3, were assessed in serum samples isolated from rats. Following anesthesia, blood samples were acquired and serum was isolated by centrifugation at 4°C for 10 min at 10,000 x g. The serum levels of CK (A032) and LDH (A020-2), of the endogenous antioxidant enzyme superoxide dismutase (SOD, A001-3), of the lipid peroxidation product malondialdehyde (MDA, A003-1) and ROS (E004), of the inflammatory factors TNF-α (H052) and IL-6 (H007), Nox (A116) and the activity of caspase-3 (G015) were determined using commercially available ELISA kits (Nanjing Jiancheng Bio-Engineering Institute Co., Ltd., Nanjing, China).

**Western blot analysis.** Heart tissue samples were washed with normal saline and lysed in radioimmunoprecipitation assay lysis buffer (RIPA; EMD Millipore, Billerica, MA, USA). The supernatants were harvested by centrifugation at 4°C for 10 min at 10,000 x g. The protein concentration was determined using a bichromonic acid protein assay kit (EMD Millipore). Equal amounts (50 μg) of extracted protein samples were separated by 6-12% SDS-PAGE, depending on molecular mass, and transferred onto polyvinylidene difluoride membranes (EMD Millipore). Membranes were blocked at room temperature with 5% fat-free milk in TBS containing Tween-20 (TBST) for 1 h and then incubated overnight at 4°C with the following primary antibodies: Anti-apoptosis regulator Bcl-2-like protein 4 (Bax; sc493; 1:500; Santa Cruz Biotechnology, Inc.,
Dallas, TX, USA; anti-B-cell lymphoma 2 (Bcl-2; sc783; 1:500; Santa Cruz Biotechnology, Inc.), anti-inducible (i)nitrative oxidase synthase (iNOS; sc49055; 1:500; Santa Cruz Biotechnology, Inc.), anti-endothelial (e)NOS, anti-nicotinamide-adenine dinucleotide phosphate (NAPDH) oxidase 4 (Nox4; ab109225; 1:2,000; Abcam, Cambridge, UK) and anti-GAPDH (1:500, sc-25778; Santa Cruz Biotechnology, Inc.). The membranes were washed 3 times with TBST and then incubated with goat anti-rabbit horseradish peroxidase-conjugated secondary antibody (sc-2004, 1:1,000; Santa Cruz Biotechnology, Inc.) at room temperature for 1 h. Protein bands were visualized using an enhanced chemiluminescence kit (ECL; Thermo Fisher Scientific, Inc., Waltham, MA, USA). Blots were semi-quantified using an image analyzer (Bio-Rad Laboratories, Inc., Hercules, CA, USA) and Image Lab version 3.0 (Bio-Rad Laboratories, Inc.).

Statistical analysis. Data are expressed as the mean ± standard deviation using SPSS version 17.0 (SPSS, Inc., Chicago, IL, USA). The statistical significance of the differences between groups was assessed by one-way analysis of variance (ANOVA) followed by a post hoc Student-Newman-Keuls test for multiple comparisons. P<0.05 was considered to indicate a statistically significant difference.

Results

Effects of anisodamine on myocardial infarct size. The effects of anisodamine on myocardial infarct sizes were investigated using a rat model of myocardial I/R. As presented in Fig. 1, myocardial infarct sizes in rats in the I/R model group were significantly increased compared with in rats of the control group. However, treatment with anisodamine was revealed to significantly limit the size of the infarcted area in rat hearts compared with the I/R model group (Fig. 1).

Effects of anisodamine on CK and LDH. The effects of anisodamine on the levels of CK and LDH were investigated in serum samples isolated from I/R model rats. The present results demonstrated a significant increase in CK and LDH levels in rats from the myocardial I/R model group compared with in rats in the control group (Fig. 2). Notably, treatment with anisodamine significantly suppressed the I/R-induced increase in CK and LDH serum levels compared with the I/R model group (Fig. 2).

Effects of anisodamine on cardiac function. The effects of anisodamine on cardiac function were investigated in rats following myocardial I/R. As presented in Fig. 3, a significant decrease in LVSP, +dp/dt max and -dp/dt max was observed in rats of the I/R model group, whereas LVEDP was significantly increased compared with in the control group. Treatment with anisodamine was revealed to attenuate the I/R-induced alterations in all parameters of cardiac function: LVSP, +dp/dt max and -dp/dt max were significantly increased, whereas the increase in LVEDP was significantly suppressed following anisodamine administration compared with rats in the I/R model group (Fig. 3).

Effects of anisodamine on the production of inflammatory factors. Compared with in rats of the control group, TNF-α and IL-6 levels in serum samples isolated from I/R rats were revealed to be significantly upregulated (Fig. 4). Notably, treatment with anisodamine was demonstrated to significantly attenuate the I/R-induced increase in the serum levels of TNF-α and IL-6 in rats compared with in the I/R model group (Fig. 4).

Effects of anisodamine on oxidative stress. In order to investigate the putative antioxidative properties of anisodamine during I/R injury, the levels of SOD and MDA were measured in serum samples isolated from rats following I/R using ELISA. As presented in Fig. 5, a significant downregulation in the levels of SOD, and an increase in MDA levels was detected in rats from the I/R model group compared with in the control group. However, treatment with anisodamine was revealed to reverse the I/R-induced alterations, as SOD serum levels were upregulated and MDA levels were decreased following anisodamine administration compared with in untreated I/R model rats (Fig. 5).

Effects of anisodamine on caspase-3 serum levels. To further investigate the effects of anisodamine on the apoptosis of myocardial cells following I/R injury, the levels of the proapoptotic protein caspase-3 were measured in serum samples using an ELISA kit. As demonstrated in Fig. 6, caspase-3 serum levels were significantly upregulated in rats following myocardial I/R compared with in the control group. However, anisodamine administration was revealed to significantly suppress the increase in caspase-3 levels compared with in untreated rats of the I/R group (Fig. 6).

Effects of anisodamine on ROS generation. As presented in Fig. 7, ROS levels in serum samples from I/R model rats were significantly increased compared with in control rats. The I/R-induced increase in ROS generation was revealed to be significantly suppressed following anisodamine treatment compared with in untreated rats from the I/R model group (Fig. 7).

Effects of anisodamine on apoptosis-associated protein expression. In order to investigate the effects of anisodamine on the mechanisms of myocardial apoptosis following I/R injury in vivo, the protein expression levels of the apoptosis-associated proteins apoptosis regulator Bcl-2 and Bax were assessed using western blot analysis. The Bax/Bcl-2 ratio in rats from the I/R model group was significantly increased compared with in control rats (Fig. 8). Notably, treatment with...
anisodamine resulted in a significant downregulation in the Bax/Bcl-2 expression ratio compared with the untreated I/R model rats (Fig. 8).

Effects of anisodamine on iNOS and eNOS protein expression. The protein expression levels of iNOS and eNOS in rats following myocardial I/R were assessed using western blot analysis (Fig. 9).
Compared with the control group, a significant upregulation in iNOS and a downregulation in eNOS protein expression was detected in myocardial tissue samples from I/R rats (Fig. 9A, B and D). Treatment with anisodamine was demonstrated to significantly inhibit the protein expression of iNOS and induce the protein expression of eNOS following I/R compared with untreated rats from the I/R model group (Fig. 9A, B and D).

### Effects of anisodamine on Nox4 protein expression and Nox activity.

Following myocardial I/R injury, the intracellular concentration of Ca$^{2+}$ is abnormally increased, resulting in the induction of myocyte apoptosis (17). Intracellular Ca$^{2+}$ overload promotes the generation of oxygen free radicals, which can damage organelle membranes, enhance intracellular acidosis and impair the mitochondrial electron transport chain. In addition, proteases, lipases and nucleases are activated, and cause plasma membrane damage, lysis of structural proteins and chromosomal damage, resulting in impaired cellular metabolism and function, which promotes I/R-induced injury (18). The results of the present study demonstrated that treatment with anisodamine attenuated myocardial infarct sizes, decreased serum CK and LDH levels, and improved cardiac function parameters, including LVSP, LVEDP, +dp/dt$\text{max}$ and -dp/dt$\text{max}$, in rats following the induction of I/R injury.

During myocardial I/R injury, the complement system is activated, which increases the production of adherence factors and the secretion of chemotactic factors (19). Inflammatory mediators, including leukotrienes, are attracted through chemotaxis, to ischemic tissues, and PMNs are recruited and activated in the site of injury. During reperfusion, ROS generation is potentiated in cardiac muscle tissue (9). Activated hemamebas adhere, transform and deposit in blocked myocardial microvessels, causing neighboring cells to enter a hypoxic state and impacting cellular metabolism (20). Activated white blood cells in the lumen of blood vessels attach to the endothelium, where they synthesize and release vasoactive substances and inflammatory mediators, thus increasing vascular permeability, triggering inflammatory responses, and ultimately contributing to endothelial and cardiomyocyte damage (20). The present study demonstrated that treatment with anisodamine significantly suppressed the I/R-induced

**Discussion**

During myocardial I/R injury, the intracellular concentration of Ca$^{2+}$ is abnormally increased, resulting in the induction of myocyte apoptosis (17). Intracellular Ca$^{2+}$ overload promotes the generation of oxygen free radicals, which can damage organelle membranes, enhance intracellular acidosis and impair the mitochondrial electron transport chain. In addition, proteases, lipases and nucleases are activated, and cause plasma membrane damage, lysis of structural proteins and chromosomal damage, resulting in impaired cellular metabolism and function, which promotes I/R-induced injury (18). The results of the present study demonstrated that treatment with anisodamine attenuated myocardial infarct sizes, decreased serum CK and LDH levels, and improved cardiac function parameters, including LVSP, LVEDP, +dp/dt$\text{max}$ and -dp/dt$\text{max}$, in rats following the induction of I/R injury.

During myocardial I/R injury, the complement system is activated, which increases the production of adherence factors and the secretion of chemotactic factors (19). Inflammatory mediators, including leukotrienes, are attracted through chemotaxis, to ischemic tissues, and PMNs are recruited and activated in the site of injury. During reperfusion, ROS generation is potentiated in cardiac muscle tissue (9). Activated hemamebas adhere, transform and deposit in blocked myocardial microvessels, causing neighboring cells to enter a hypoxic state and impacting cellular metabolism (20). Activated white blood cells in the lumen of blood vessels attach to the endothelium, where they synthesize and release vasoactive substances and inflammatory mediators, thus increasing vascular permeability, triggering inflammatory responses, and ultimately contributing to endothelial and cardiomyocyte damage (20). The present study demonstrated that treatment with anisodamine significantly suppressed the I/R-induced

---

**Figure 5. Effects of anisodamine on oxidative stress.** Treatment with anisodamine reversed the I/R-induced alterations in (A) SOD and (B) MDA serum levels compared with the I/R model group. Data are expressed as the mean ± standard deviation. *P<0.05 vs. the control group; #P<0.05 vs. the MI/R group. MI/R, myocardial ischemia/reperfusion; SOD, superoxide dismutase; MDA, malondialdehyde; ANI, anisodamine.

**Figure 6. Effects of anisodamine on caspase-3 serum levels.** Treatment with anisodamine significantly suppressed the I/R-induced increase in caspase-3 serum levels compared with the I/R model group. Data are expressed as the mean ± standard deviation. *P<0.05 vs. the control group; #P<0.05 vs. the MI/R group. MI/R, myocardial ischemia/reperfusion; ANI, anisodamine.

**Figure 7. Effects of anisodamine on ROS generation.** Treatment with anisodamine significantly suppressed the I/R-induced increase in ROS generation compared with the I/R model group. Data are expressed as the mean ± standard deviation. *P<0.05 vs. the control group; #P<0.05 vs. the MI/R group. ROS, reactive oxygen species; MI/R, myocardial ischemia/reperfusion; ANI, anisodamine.
increase in TNF-α and IL-6 serum levels in rats following the induction of I/R injury. In accordance with the present results, Xu et al (21) reported that anisodamine suppressed T helper cell type 2-associated responses and eosinophil-mediated inflammatory processes in a murine model of allergic asthma.

The mitochondrial electron transport chain and Nox are primarily responsible for ROS generation under physiological conditions. During myocardial I/R injury, ROS production from the mitochondria and Nox is implicated in oxidative stress injury in cardiomyocytes (22). Nox is an enzyme also expressed in phagocytes; however, Nox in myocardial cells differs in its catalytic characteristics and biological functions: Cardiac muscle Nox is weakly active under physiological conditions, whereas ROS production is a critical function of phagocytosis; cardiac Nox and NADPH or nicotinamide adenine dinucleotide (NADH) are electron donors, whereas only NADPH is an electron donor in phagocytes; in phagocytes, Nox-generated ROS mainly participate in the host mechanisms of defense (23,24), whereas in cardiomyocytes ROS function as a second messenger during the regulation of cellular proliferation and differentiation (22). The results of the present study revealed that anisodamine significantly reversed the I/R-induced decrease in SOD levels and increase in MDA levels in serum samples isolated from rats following I/R. In accordance with the present results, Liu et al (25) reported that anisodamine attenuated oxidative stress-induced mitochondrial injury in swine with cardiac arrest.

Nox4 exhibits characteristics that distinguish it from other members of the Nox family of enzymes: Nox2 and Nox1 share a high sequence homology, whereas the amino acid sequence of Nox4 exhibits only a 39% homology with other Nox members, suggesting a corresponding difference in Nox4 structure. In
addition, under physiological conditions, Nox4 activity is independent of regulatory subunits and is constitutively active; the activity of Nox4 is mainly controlled by its expression levels. Due to differences in their activation mechanisms, Nox2 needs to be induced in order to generate O$_2^-$, whereas Nox4 can constitutively generate low levels of H$_2$O$_2$(26). Furthermore, Nox4 in cardiac muscle cells can catalyze O$_2^-$ generation effectively, using NADH as a hydrogen donor (23). Due to the autonomous activity of Nox4, NADH is highly used in cardiac muscle cells (26). The results of the present study demonstrated that anisodamine significantly suppressed the I/R-induced upregulation in Nox4 protein expression and Nox activity in I/R model rats in vivo.

ROS and ROS-mediated oxidative stress responses have been implicated in cardiac hypertrophy induced by α-adrenergic agonists, angiotensin II, endothelin (ET)-1 and TNF-α (23). Nox2 and Nox4 in cardiac muscle cells have also been reported to participate in the development and progression of cardiac hypertrophy and fibrosis (18). Nox2 has been demonstrated to exacerbate hypertension triggered by cardiac hypertrophy, interstitial fibrosis and aldosterone/salt overload, whereas the expression of Nox4 can increase following stimulation by angiotensin II, α-adrenergic agonists and hypertension (18). Nox4 is the main source of ROS in the hypertrophic heart (23). The results of the present study demonstrated that treatment with anisodamine significantly attenuated the I/R-induced increase in ROS generation in rat myocardial tissue in vivo.

Under physiological conditions, NO is released by the vascular endothelium and serves an important protective role for endothelial function (27). ET contents in the circulation are low under physiological conditions, and its effects on the endothelium are negligible (27). During I/R injury, the endothelial synthesis and release of NO is reduced, weakening antagonist oxygen radicals, and its protective effects on the endothelium are lost, thus further aggravating vascular endothelial injury and forming a vicious cycle during the pathogenesis of I/R injury (28). Previous studies have reported that during myocardial I/R, the plasma NO concentrations are reduced and the ET concentrations are increased (27,28). In the present study, anisodamine was revealed to significantly downregulate the protein expression of iNOS and upregulate the expression of eNOS, thus counteracting the I/R-induced dysfunctions in NO production in vivo.

In conclusion, the present study demonstrated that anisodamine exerted cardioprotective effects against myocardial I/R injury, through the inhibition of oxidative stress, inflammation and apoptosis, via targeting the expression of NOS and Nox, and the production of ROS. The present results suggested that anisodamine may have potential as an alternative therapeutic strategy for the treatment of patients with myocardial infarction.

References


